Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse

Although first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy is effective for treating EGFR-mutant non–small cell lung cancer (NSCLC), it is now understood that drug-tolerant persister (DTP) cells escaping from initial treatment eventually drives drug resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Meng, Chen, Na, Pang, Huanhuan, Jiang, Tao, Jiang, Wei, Tian, Panwen, Yao, LiAng, Chen, Yangzi, DeBerardinis, Ralph J., Li, Weimin, Yu, Qitao, Zhou, Caicun, Hu, Zeping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566900/
https://www.ncbi.nlm.nih.gov/pubmed/36048538
http://dx.doi.org/10.1172/JCI160152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9566900/
https://www.ncbi.nlm.nih.gov/pubmed/36048538
http://dx.doi.org/10.1172/JCI160152

Ejemplares similares